The presence of TEL/AML1 fusion gene in childhood acute lymphoblastic leukaemia (ALL) defines a subgroup of patients with better than average outcome. However, the prognostic significance of this aberration has recently been disputed by the Berlin-Frankfurt-Mü nster (BFM) study group due to its relatively high incidence found in relapsed patients ( 
Introduction
TEL/AML1 fusion gene is one of the most common non-random genetic aberrations in childhood acute lymphoblastic leukaemia (ALL) and is considered an independent good prognostic factor. The probability of 5-year event-free survival (EFS) for TEL/AML1-positive patients is 87-100%. [1] [2] [3] [4] However, the Berlin-Frankfurt-Mü nster (BFM) study group recently presented data questioning the better prognosis of such patients. Two recent studies reported a high frequency of TEL/AML1-positive children with relapsed ALL. 5, 6 The two studies referred to 46 and 146 relapsed patients with an incidence of TEL/AML1 fusion gene of 19.6% and 21.9%, respectively. The investigators concluded that this incidence, similar to that reported at presentation, may imply that the appearance of the TEL/AML1 rearrangement per se is not a good prognostic factor and that the only significant difference between the TEL/AML1-negative and -positive subgroups was the duration of complete remission. The intervals for the first and also for the second remission were approximately 1 year longer in TEL/AML1-positive children and the period before relapse was more than 2 years after the start of the therapy in the vast majority of children.
In contrast, ongoing retroprospective studies in the Czech Republic show significantly lower incidence of this fusion gene in 45 unselected patients who relapsed within 46 months. Although TEL/AML1 detection was frequently established as a possible method for MRD detection, only few MRD follow-up results has been reported so far. [7] [8] [9] Here we present notable differences of minimal residual disease (MRD) levels among 33 newly diagnosed TEL/AML1-positive patients during initial treatment.
Materials and methods
Between October 1994 and July 1998, a total of 60 children with ALL relapsed in the Czech Republic. Bone marrow (BM) and/or peripheral blood (PB) samples were available for 45 of them. All children were younger than 18 years at diagnosis and had been initially treated according to ALL BFM protocols 83 to 95 in one of the seven centres of the Czech Paediatric Haematology Working Group, except for one patient who received initial treatment in Slovakia. Samples were examined by reverse transcriptase-polymerase chain reaction (RT-PCR); the one-step amplification of ABL exons a2/a3 was used as cDNA quality control. The TEL/AML1 fusion gene was amplified in a two-round nested PCR as described previously, 10 with a detection sensitivity of 10 −5 verified by serial dilution of presentation samples into nucleated blood cells of a healthy volunteer donor. In addition, patients were routinely screened for expression of BCR/ABL and MLL/AF4 rearrangements. Patients classified as pro-B ALL, common ALL and pre-B ALL are categorised as B cell precursor (BCP) ALL.
Results and discussion
Among the total of 45 consecutive relapsed patients examined in our laboratory, only four were positive for the TEL/AML1 rearrangement (8.9%). Four patients exhibited other fusion genes -BCR/ABL (n = 2) and MLL/AF4 (n = 2), respectively. All four TEL/AML1-positive children and the majority of patients in the TEL/AML1-negative group had a BCP immunophenotype (BCP ALL 73% (30/41), T lineage ALL 22% (9/41), mature B cell ALL 5% (2/41) in the negative group). All patients with TEL/AML1 fusion were examined at first relapse; an original diagnostic sample was available from one of them and was also shown to be positive. In contrast to data obtained in our cohort of newly diagnosed patients 11 the age at presentation within the TEL/AML1-positive group (1, 3, 3 and 13 years) did not differ significantly from the negative group (0-17 years, median 5 years), likely due to the small number of positive patients. In agreement with previously published data, the first remission duration was longer for TEL/AML1-positive patients (24-89 months, median 32.5 months) than in the negative group (2-149 months, median 18 months; Mann-Whitney test: P = 0.02).
The frequency of TEL/AML1-positive patients at presentation, based on retroprospective evaluation of newly diagnosed childhood ALL (March 1995 to July 1998), is significantly higher in our population (41/190 patients, 21.6%) than the frequency at relapse (8.9%; Fischer's exact test, P = 0.035). In the cohort of relapsed BCP-ALLs, the proportion of TEL/AML1-positive children (11.8%) is notably lower than in the group of newly diagnosed patients with the same immunophenotype (25.5%) and lower than in the corresponding Harbott's 5 and Seeger's 6 groups (27% and 22.5%, respectively). There are some unusual aspects regarding the characteristics of the cohorts of relapsed patients in both German studies. Primarily, only 36% (146/408) of all relapsed patients in the study of Seeger et al were tested for the presence of TEL/AML1 fusion. Moreover, there is a strikingly low frequency of T lineage ALL among relapses in Seeger's cohort (4/146). Considering these two facts, a possible selection bias cannot be excluded in Seeger's study. In the Harbott's study, the initial treatment is not uniform: among nine TEL/AML1-positive patients in this study only six were treated according to BFM protocols, two according to CoALL-05-92 and one patient was even initially treated for AML. In comparison, we tested 45 (75%) of the 60 patients who relapsed within a 46-month period of the Czech national study. The characteristics of 15 remaining patients, whose samples were not available for molecular genetic analysis, do not differ from the tested cohort when considering immunophenotype, presenting age and first complete remission duration (BCP-ALL 67% (10/15), T-ALL 27% (4/15), not done 7% (1/15); age at diagnosis 0-17, median 5 years; first CR 7-50, median 17 months). We are not aware of any biological factor that could discriminate these 15 patients from the examined cohort. All 60 children who relapsed from October 1994 in the Czech Republic were treated according to BFM protocols. Nevertheless, our data confirm that relapses do occur also among TEL/AML1-positive children.
No additional prognostic factors are yet known that could divide the group of TEL/AML1-positive patients at presentation according to probability of subsequent relapse. In the search for a means of stratification of the patients, we utilised TEL/AML1 detection for monitoring MRD during treatment. A total of 75 samples were available for 33 of 41 newly diagnosed TEL/AML1-positive children. At day +15 most of the tested children (6/8) had detectable residual disease at levels of 10 −5 to 10 −2 . Subsequently, 10 of 24 patients examined at day +33, the end of induction therapy (7 days of steroid therapy followed by vincristine, prednisone, daunorubicin, Lasparaginase and intrathecal chemotherapy), expressed at least low levels (10 −5 to 10 −4 ) of MRD; in one of them (UPN 148) the TEL/AML1-fusion expression corresponded to the level of one malignant cell among less then 1000 normal cells (10 −2 to 10 −3 ). This level is generally considered highly predictive for subsequent relapse. 12 Consequently, this patient presented with other unfavourable features including high leu-kocyte count (WBC Ͼ260 × 10 9 /l), CNS infiltration and poor response to prednisone pretreatment. Moreover, we found positivity on two out of five occasions, even after allogeneic BMT performed in first complete remission in this patient. In addition, five other patients had detectable MRD in one sample later during treatment at the sensitivity threshold level of the method (10 −5 ). The end of induction therapy sample (day +33) was available in four of them and in all four cases was positive. In contrast, none of the patients with a negative result after induction had any positive test later during continuation treatment (total 15 samples). For details see Figure 1 . However, a MRD sensitivity level 10 −5 can seldom be reached by other MRD detection methods including monitoring of IgH and TCR genes rearrangements. In accordance with previously published data, only high levels (у10 ) of MRD seemed to be predictive for subsequent relapse. Relevance of low MRD levels of TEL/AML1-positive cells has not been established as yet; patients with low MRD levels should be monitored but there is no evidence, so far, that they are at higher risk of relapse than the patients without detectable MRD. Thus, probability of relapse after conventional therapy seems to have been higher for patient UPN 148 than for other patients in the study. Following allogeneic BMT, his risk cannot be determined solely by the MRD status as data on similar patients are rarely documented.
Contradictions over the incidence of TEL/AML1-positive patients with relapsed ALL among children treated by identical or similar protocols suggest that the prognostic significance of TEL/AML1 fusion is still unclear and that larger prospective studies are necessary. 13 The results of our MRD study seem to be very promising but they need further confirmation. Monitoring of children with detectable MRD at the end of induction therapy could contribute to elucidation of the prognostic value of MRD detection in TEL/AML1-positive children as well as TEL/AML1 expression itself.
Note added in proof
At the time of processing the manuscript, patient UPN 148 has relapsed in BM and PB at day +201 after BMT.
